Literature DB >> 23128368

Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994.

Jeffrey C Sirota1, Kim McFann, Giovanni Targher, Michel Chonchol, Diana I Jalal.   

Abstract

BACKGROUND/AIMS: Nonalcoholic fatty liver disease (NAFLD) has been proposed to contribute to chronic kidney disease (CKD) independently of traditional cardiometabolic risk factors. We hypothesized that NAFLD is associated with CKD and that greater severity of NAFLD is associated with higher odds of CKD.
METHODS: A cross-sectional analysis of 11,469 adults who participated in the National Health and Nutrition Examination Survey (NHANES) 1988-1994. NAFLD was defined by ultrasonographic detection of steatosis in the absence of other liver diseases. CKD was defined as an estimated glomerular filtration rate of ≤60 ml/min/1.73 m(2) or the presence of albuminuria in subjects with an estimated glomerular filtration rate of >60 ml/min/1.73 m(2).
RESULTS: 2,891 (25.4%) patients in the cohort had CKD. The prevalence of NAFLD was higher in individuals with CKD compared to those without CKD (42.2 vs. 34.5%, p < 0.0001). NAFLD was associated with CKD in unadjusted logistic regression analysis (OR = 1.47, 95% CI: 1.29-1.67, p < 0.0001). Adjustment for demographics and components of metabolic syndrome attenuated this relationship (OR = 1.04, 95% CI: 0.88-1.23, p = 0.64). Moderate and severe NAFLD on ultrasound were increasingly associated with prevalent CKD in unadjusted analysis, but not after adjustment for metabolic syndrome components.
CONCLUSION: After adjusting for features of metabolic syndrome, ultrasound-diagnosed NAFLD is not associated with prevalent CKD among US adults. Aggressive public health efforts are needed to prevent and treat metabolic syndrome.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23128368      PMCID: PMC3563287          DOI: 10.1159/000343885

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  25 in total

1.  Liver: an alarm for the heart?

Authors:  Seyed Amir Mirbagheri; Armin Rashidi; Seifollah Abdi; Daryoush Saedi; Mehdi Abouzari
Journal:  Liver Int       Date:  2007-09       Impact factor: 5.828

2.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

3.  Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.

Authors:  Giorgio Bedogni; Lucia Miglioli; Flora Masutti; Claudio Tiribelli; Giulio Marchesini; Stefano Bellentani
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

Review 4.  Review article: role of oxidative stress in the progression of non-alcoholic steatosis.

Authors:  E Albano; E Mottaran; G Occhino; E Reale; M Vidali
Journal:  Aliment Pharmacol Ther       Date:  2005-11       Impact factor: 8.171

Review 5.  Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.

Authors:  Brent A Neuschwander-Tetri; Stephen H Caldwell
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

6.  Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults.

Authors:  S Jimba; T Nakagami; M Takahashi; T Wakamatsu; Y Hirota; Y Iwamoto; T Wasada
Journal:  Diabet Med       Date:  2005-09       Impact factor: 4.359

7.  Predictors of new-onset kidney disease in a community-based population.

Authors:  Caroline S Fox; Martin G Larson; Eric P Leip; Bruce Culleton; Peter W F Wilson; Daniel Levy
Journal:  JAMA       Date:  2004-02-18       Impact factor: 56.272

8.  The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation.

Authors:  Masahide Hamaguchi; Takao Kojima; Yoshito Itoh; Yuichi Harano; Kota Fujii; Tomoaki Nakajima; Takahiro Kato; Noriyuki Takeda; Junichi Okuda; Kazunori Ida; Yutaka Kawahito; Toshikazu Yoshikawa; Takeshi Okanoue
Journal:  Am J Gastroenterol       Date:  2007-09-25       Impact factor: 10.864

Review 9.  Non-alcoholic fatty liver disease: the mist gradually clears.

Authors:  Nimantha Mark Wilfred de Alwis; Christopher Paul Day
Journal:  J Hepatol       Date:  2008-02-04       Impact factor: 25.083

10.  Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men.

Authors:  Yoosoo Chang; Seungho Ryu; Eunju Sung; Hee-Yeon Woo; Eunock Oh; Kyungsoo Cha; Eunmi Jung; Won Sool Kim
Journal:  Metabolism       Date:  2008-04       Impact factor: 8.694

View more
  26 in total

1.  Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis.

Authors:  Robert M Wilechansky; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Emelia J Benjamin; Michelle T Long
Journal:  Liver Int       Date:  2019-05-24       Impact factor: 5.828

2.  Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study.

Authors:  Haesuk Park; Ghadeer K Dawwas; Xinyue Liu; Mindie H Nguyen
Journal:  J Intern Med       Date:  2019-08-23       Impact factor: 8.989

3.  Liver steatosis and the risk of albuminuria: the multi-ethnic study of atherosclerosis.

Authors:  Ravi V Shah; Matthew A Allison; Joao A C Lima; Siddique A Abbasi; Morgana Mongraw-Chaffin; Michael Jerosch-Herold; Jingzhong Ding; Matthew J Budoff; Venkatesh L Murthy
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

4.  Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease.

Authors:  Chan-Young Jung; Geun Woo Ryu; Hyung Woo Kim; Sang Hoon Ahn; Seung Up Kim; Beom Seok Kim
Journal:  Diabetologia       Date:  2021-12-21       Impact factor: 10.122

5.  Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetes.

Authors:  Yongqiang Li; Shuangshuang Zhu; Bin Li; Xiaofei Shao; Xinyu Liu; Aiqun Liu; Bifang Wu; Ying Zhang; Honglei Wang; Xiaohong Wang; Kangping Deng; Qin Liu; Min Huang; Hongmei Liu; Harry Holthöfer; Hequn Zou
Journal:  Int Urol Nephrol       Date:  2014-08-07       Impact factor: 2.370

6.  High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease.

Authors:  Huang-Wei Xu; Yung-Chien Hsu; Chia-Hao Chang; Kuo-Liang Wei; Chun-Liang Lin
Journal:  Hepatol Int       Date:  2015-12-16       Impact factor: 6.047

Review 7.  Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.

Authors:  Silvia Fargion; Marianna Porzio; Anna Ludovica Fracanzani
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

8.  Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018.

Authors:  Yunlei Deng; Qianwen Zhao; Rong Gong
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-22       Impact factor: 3.168

9.  The Association between Decreased Kidney Function and FIB-4 Index Value, as Indirect Liver Fibrosis Indicator, in Middle-Aged and Older Subjects.

Authors:  Kazuko Kotoku; Ryoma Michishita; Takuro Matsuda; Shotaro Kawakami; Natsumi Morito; Yoshinari Uehara; Yasuki Higaki
Journal:  Int J Environ Res Public Health       Date:  2021-06-29       Impact factor: 3.390

Review 10.  Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Giovanni Musso; Roberto Gambino; James H Tabibian; Mattias Ekstedt; Stergios Kechagias; Masahide Hamaguchi; Rolf Hultcrantz; Hannes Hagström; Seung Kew Yoon; Phunchai Charatcharoenwitthaya; Jacob George; Francisco Barrera; Svanhildur Hafliðadóttir; Einar Stefan Björnsson; Matthew J Armstrong; Laurence J Hopkins; Xin Gao; Sven Francque; An Verrijken; Yusuf Yilmaz; Keith D Lindor; Michael Charlton; Robin Haring; Markus M Lerch; Rainer Rettig; Henry Völzke; Seungho Ryu; Guolin Li; Linda L Wong; Mariana Machado; Helena Cortez-Pinto; Kohichiroh Yasui; Maurizio Cassader
Journal:  PLoS Med       Date:  2014-07-22       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.